SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing significant volatility and a steep sell-off after disclosing that Marvell canceled its purchase orders due to a confidentiality breach caused by public remarks from management. The community is sharply divided, with many retail investors expressing frustration over the lack of transparency while others view the dip as an opportunity to accumulate shares, betting on the long-term viability of the company's photonics technology.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk (SNDK) is surging toward record highs, driven by explosive AI-related demand for its NAND memory and intense speculation surrounding a potential stock split ahead of its upcoming earnings report. The community remains deeply divided, with bulls pointing to robust fundamentals and a 'memory supercycle,' while bears remain skeptical of the stock's parabolic valuation and fear an imminent correction.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is seeing significant market activity driven by the potential integration of its chips into future AI-agentic smartphone platforms and broader AI infrastructure. While the community is actively debating the stock's valuation and the company's long-term competitive positioning, investors are closely watching upcoming earnings as a potential catalyst to clear current overhead supply.

High Roller Technologies, Inc. is an evolving and growth-oriented iCasino and entertainment company, which engages in the business of operating an online gaming business offering casino betting games to customers. The firm also offers a wide range of games including many that are available in land-based casinos, such as blackjack, roulette, baccarat, poker, and slot machines. The company was founded by Michael Alexander Cribari and Brandon Christopher Eachus on December 21, 2021 and is headquartered in Las Vegas, NV.

High Roller Technologies Inc.

High Roller Technologies Inc

High Roller Technologies is experiencing significant community momentum as investors anticipate the official U.S. launch of its predictive betting platform, a move bolstered by recent strategic marketing partnerships. Market participants are actively discussing a potential squeeze driven by a tight float, high short interest, and the stock's positioning as a pure-play opportunity in the rapidly expanding predictive betting sector.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

HTCO is seeing significant retail attention driven by high volatility and heavy short interest, leading traders to discuss the potential for a short squeeze despite skepticism surrounding the company's fundamentals and recent price action. The community remains divided, with some actively trading the sharp price swings while others warn of the risks associated with the stock's unpredictable performance.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is experiencing high volatility as investors weigh the potential for government contract awards against frustration with management's communication regarding timelines and guidance. The community is focused on the company's drone integration with U.S. military platforms and remains split between optimism for future revenue growth and skepticism over the timing of major defense milestones.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for investors following the release of positive Phase 3 clinical trial results, though the stock's price action has been marked by high volatility and intense debate among traders. While the community is actively discussing the company's long-term potential in gene-editing, significant disagreement persists over the efficacy of the data, the impact of potential dilution from an at-the-market offering, and the heavy influence of short sellers on the stock's movement.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is facing heightened selling pressure and negative sentiment due to concerns over regulatory uncertainty, particularly regarding the impact of proposed legislation and the competitive landscape of prediction markets. Community discourse remains deeply divided, with bearish investors citing management's consistent share selling and weak stock performance, while long-term bulls point to potential expansion opportunities and the belief that the stock is currently undervalued.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is hitting record highs as market participants continue to aggressively chase AI momentum, with discussions heavily focused on sustained data center demand and the stock's role as a foundational infrastructure play. While some investors are wary of the stock's parabolic climb and valuation, the broader community remains fiercely bullish, viewing any minor pullbacks as buying opportunities amid a broader rally in the semiconductor sector.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences is currently seeing significant investor attention following positive Phase 3 clinical trial results for its acne treatment and ongoing developments in its MASH pipeline, including combination therapy efforts. The community is actively debating the stock's potential for acquisition, with discussions highlighting its discounted valuation relative to other MASH-focused biotech buyouts and its recent analyst upgrades.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CorMedix (NASDAQ:CRMD) Earns Buy Rating from D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and issued a $14.00 target price on shares of CorMedix in a research note on Monday...

Phocas Financial Corp. Takes $1.99 Million Position in CorMedix Inc $CRMD

Phocas Financial Corp. bought a new position in shares of CorMedix Inc (NASDAQ:CRMD - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange...

CorMedix Outlines Post-Melinta Growth, Q2 REZZAYO Phase 3 Catalyst and DefenCath Reimbursement Shift

CorMedix (NASDAQ:CRMD) Chief Executive Officer Joe Todisco outlined the company's evolving strategy and upcoming catalysts during a fireside chat at Needham & Company's 25th Annual Healthcare...

CorMedix Inc (NASDAQ:CRMD) Receives Average Recommendation of "Moderate Buy" from Analysts

CorMedix Inc (NASDAQ:CRMD - Get Free Report) has earned an average rating of "Moderate Buy" from the eight brokerages that are presently covering the stock, MarketBeat reports. One research analyst...

Phocas Financial Corp. bought a new stake in shares of CorMedix Inc (NASDAQ:CRMD - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 171,087 shares of the company's stock, valued at approximately $1,990,000. Phocas Financial Corp. owned 0.22% of...

Strength Seen in MeiraGTx (MGTX): Can Its 6.2% Jump Turn into More Strength?

MeiraGTx (MGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Do Options Traders Know Something About CorMedix Stock We Don't?

Investors need to pay close attention to CRMD stock based on the movements in the options market lately. 

CorMedix (CRMD) Expected to Announce Earnings on Tuesday

CorMedix (NASDAQ:CRMD) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 31. (View Earnings Report at...

CorMedix Inc (NASDAQ:CRMD) Given Consensus Rating of "Moderate Buy" by Brokerages

CorMedix Inc (NASDAQ:CRMD - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eight research firms that are currently covering the stock, Marketbeat.com reports. One...

CorMedix Inc $CRMD Shares Bought by Divisadero Street Capital Management LP

Divisadero Street Capital Management LP boosted its holdings in shares of CorMedix Inc (NASDAQ:CRMD - Free Report) by 305.7% during the third quarter, according to its most recent disclosure with the...

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Earnings

Fed / Macro data

Headlines / Geopolitics

Other (drop a comment)

What will be the main driver of the market this week?

Stocktwits

Stocktwits Polls

Investors are weighing the positive topline results for Rezzayo against the challenge of non-inferiority benchmarks in clinical trials.

Bullish investors are speculating that positive clinical outcomes and institutional backing could increase the likelihood of a strategic acquisition.

Current Price	$7.72
Prev Close	$7.42
Open	$7.53
Dividend Yield	0.00%
50-Day Moving Average	$6.96
Beta	1.04
Avg. Volume	1.64M
PE Ratio	3.74

52-Week High	$17.43
52-Week Low	$6.13
Market Capitalization	$581.94M
EPS (Annual)	$2.03
Price to Book	1.45
Revenue Per Employee	$1.63M

CRMD
CorMedix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRMD News

CRMDCorMedix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRMD News

CRMD
CorMedix Inc